FDA APPROVES ENDOLOGIX'S POWERLINK-120 ELG

Endologix has received FDA approval to market new short body-short limb variants of the PowerlinkSystem endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms (AAA).

The two Powerlink-120 models should address the 5 to 10 percent of AAA patients currently excluded from treatment because of "anatomical considerations," the company said. Endologix plans to market the new devices beginning in May.